Current Headlines

  1. Integrated Project Services, LLC (IPS) And G-CON Manufacturing Introduce iCON, A Turnkey Modular Facility Platform Solution For BioManufacturing
    9/21/2017

    IPS-Integrated Project Services, LLC (IPS), a leading global provider of engineering, architecture, project controls, construction management, commissioning and qualification services, and G-CON Manufacturing, Inc. the leading provider of prefabricated cleanrooms, today announced the unveiling of the iCON™ brand which represents the collective facility design and build capabilities of the two companies.

  2. Brammer Bio Completes Expansion Of Cell And Gene Therapy Clinical Manufacturing Facilities In Florida
    9/18/2017

    Brammer Bio ("Brammer"), a cell and gene therapy contract development and manufacturing organization (CDMO), today announced completion of its clinical capacity expansion in Alachua, Florida.

  3. Kaneka Eurogentec Announces The Construction Of A New Large Scale Pharmaceutical Grade Biologics Manufacturing Facility
    9/12/2017

    Kaneka Eurogentec, a custom service and FDA inspected contract development and manufacturing organization (CDMO), announced recently that its board has approved the construction of a new state of-the-art GMP facility adjacent to its current facility and equipped with a 2200 L fermenter.

  4. Pfizer Presents Positive Pivotal Data for PF-05280014, an Investigational Biosimilar to Herceptin (trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress
    9/11/2017

    Pfizer Inc. (NYSE:PFE) today announced positive findings from REFLECTIONS B327-02 (n=707), a pivotal Phase 3 randomized, double-blind comparative safety and efficacy study of the company’s investigational trastuzumab biosimilar (PF-05280014) versus Herceptin 1(trastuzumab), at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid. Positive data from a supplemental study, REFLECTIONS B327-04 (n=226), were also presented at the meeting. PF-05280014 is being developed by Pfizer as a potential biosimilar to Herceptin.

  5. CRB Provides Modern Facility Design For Bayer North America Crop Science Headquarters
    9/7/2017

    Bayer’s North American Crop Science Division Headquarters required a modernization to be reflective of a modern brand, accommodate increased staff levels and attract professionals to Bayer. CRB provided mechanical, electrical and plumbing services to help create an efficient, modern facility within the existing building envelope on Bayer’s growing campus.

  6. Outsourced Pharma San Francisco 2017 Agenda Update
    9/6/2017

    Outsourced Pharma San Francisco will feature Achaogen as its Spotlight Leadership Company at its conference for professionals of biotech, pharma, and contract development and manufacturing organizations (October 17 - 18 at the Hyatt Regency San Francisco Airport). The session is titled: Spotlight Leadership Company: Achaogen.

  7. BPOG, NIIMBL To Collaborate On U.S.-Specific Roadmap For Biopharmaceutical Manufacturing Industry
    9/5/2017

    BioPhorum Operations Group (BPOG) and the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) are pleased to announce they have entered into a collaboration agreement to develop a US-specific roadmap for the biopharmaceutical manufacturing industry to complement the existing BPOG global roadmap.

  8. Beckman Coulter Expands Detection Boundaries Of CytoFLEX Flow Cytometry Platform
    9/5/2017

    Beckman Coulter Life Sciences has opened up the possibilities for cancer researchers with the launch of the first flow cytometer to offer excitation sources across the visible spectrum in a standard configuration.

  9. Coherus BioSciences Announces Positive Topline Results For Clinical Pharmacokinetic Bioequivalence Study for CHS-1420 (Humira Biosimilar Candidate) Versus European Marketed Humira In Healthy Subjects
    8/28/2017

    Coherus BioSciences today reported topline results from the first of three ongoing pharmacokinetic bioequivalence ("PK/BE") studies comparing CHS-1420, a proposed adalimumab ("Humira") biosimilar candidate versus European marketed Humira.

  10. Samsung Bioepis and Takeda Sign Strategic Collaboration Agreement to Co-Develop Multiple Novel Biologic Therapies
    8/21/2017

    Samsung Bioepis Co., Ltd. announced today that it has entered into a strategic collaboration agreement with Takeda Pharmaceutical Company to jointly fund and co-develop multiple novel biologic therapies in unmet disease areas. The two companies will immediately begin working on the program’s first therapeutic candidate, TAK-671, which is intended to treat severe acute pancreatitis.